Day One Biopharmaceuticals股价在收购宣布后飙升至52周高点，尽管季度亏损且法律审查仍在持续。 Day One Biopharmaceuticals shares surged to a 52-week high after a buyout announcement, despite a quarterly loss and ongoing legal scrutiny.

Day One Biopharmaceuticals（DAWN）股价上涨至52周高点21.23美元，涨幅8.43美元，成交量大幅，此前收购宣布引发交易暂停并增加买权活动。 Day One Biopharmaceuticals (DAWN) shares rose to a 52-week high of $21.23, gaining $8.43, on heavy volume, following a buyout announcement that triggered a trading halt and surge in call-option activity. 该公司报告每季度每股损失21美元,损失估计数为4美元,但5 372万美元的收入超过了4 981万美元的共识。 The company reported a quarterly loss of $0.21 per share, missing estimates by $0.04, but revenue of $53.72 million surpassed the $49.81 million consensus. 分析师提供混合评级,一致的“持有”或“中价购买”,平均价格目标为25.56美元至26.14美元。 Analysts offer mixed ratings, with a consensus "hold" or "moderate buy," and a $25.56 to $26.14 average price target. 对买断交易的公平性进行法律调查可能会延误或改变交易。 Legal investigations into the buyout’s fairness may delay or alter the deal. 该股票的市场上限为21.9亿美元,负P/E,机构所有权占87.95%。 The stock has a market cap of $2.19 billion, negative P/E, and 87.95% institutional ownership. 内幕人士近几个月出售股票,将其股权减少到6.20%。 Insiders sold shares in recent months, reducing their stake to 6.20%.